Tommy G. Thompson - Jul 7, 2022 Form 4 Insider Report for UNITED THERAPEUTICS Corp (UTHR)

Role
Director
Signature
/s/ John S. Hess, Jr. under Power of Attorney
Stock symbol
UTHR
Transactions as of
Jul 7, 2022
Transactions value $
$0
Form type
4
Date filed
7/8/2022, 05:41 PM
Previous filing
May 26, 2022
Next filing
Aug 22, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction UTHR Common Stock Options Exercise $0 +1.08K +16.56% $0.00 7.6K Jul 8, 2022 Direct F1
holding UTHR Common Stock 5.8K Jul 7, 2022 Family LLC
holding UTHR Common Stock 8.2K Jul 7, 2022 Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction UTHR Restricted Stock Unit Options Exercise $0 -1.08K -100% $0.00* 0 Jul 8, 2022 Common Stock 1.08K $0.00 Direct F2, F3
transaction UTHR Restricted Stock Unit Award $0 +880 $0.00 880 Jul 7, 2022 Common Stock 880 $0.00 Direct F2, F3, F4, F5
transaction UTHR Stock Options Award $0 +2.49K +100% $0.00 4.98K Jul 7, 2022 Common Stock 2.49K $240.20 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares received upon vesting of restricted stock units on July 8, 2022. Restricted stock units converted on a one-for-one basis into shares of common stock.
F2 Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.
F3 Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.
F4 Annual non-employee director award.
F5 The reporting person has elected to defer receipt of the shares upon conversion of t his award until on or about July 7, 2024.